Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We had a solid quarter in new starts related to tubeless pumps and for the first time we overcame tube of based pumps in terms of new starts |
| So we think the second half is going to be stronger than the first |
| Free cash flow of $143 million improved significantly over 2022, led by DSO improvement of 1.5 days and significantly improved CapEx management |
| We also believe that increased insurance coverage of CGMs, especially in the government sector, is a strong tailwind |
| It’s also noteworthy that adjusted EBITDA grew faster than revenue, largely as a result of the cost-out program and technology-driven operating improvements |
| Our adherence performance met our expectations and resupply continues to be very strong |
| We have a favorable debt structure with a good portion of our debt in longer terms at attractive fixed rates |
| We ended the year in a position of strength as we've built a solid foundation to grow |
| We expect to improve free cash flow generation over 2023 by 15% at the mid-point as we're already securing efficiencies in procuring and managing our CapEx and inventory |
| Jason will give you more detail, but our top line for the year grew 16%, powered by a 12% increase in our resupply census which resulted in record volumes |
| Our sleep census, which is a combination of new starts and ongoing path resupply, continues to grow at a pace that bodes well for future revenue growth |
| To your point of rental, our new start growth is strong, patient demand is strong, frankly as strong as it's ever been |
| We have more than 300 sleep coaches whose job is to improve the patient experience, which we also believe is best in class |
| So just continuing to compound that census, so we feel great about resupply in 2024 |
| We're expecting higher-single digit in the resupply operations as we just continue to increase the average sales price and number of products per order as well as improving our adherence rates |
| Here again, driven by the expertise of our respiratory therapists, we believe we have increased our share and are striving to become number one in this product category two |
| During 2023, we paid down $45 million of our term-loan including a $10 million voluntary payment in the fourth quarter as a result of our strong free cash flow |
| We want our patients to be healthier, so this is good news |
| Stated simply, we had a terrific fourth quarter and ended 2023 with a great deal of positive momentum throughout our business |
| Like Richard, I was very pleased with the fourth quarter results |
| And so the company was able to deliver on that that cost containment program and then also deliver what I think is about $80 million of growth over the prior year |
| Humana, to your point we have done a good job transitioning patients, and we have gone faster than we committed to, which is resulting in a big improvement in Q4 over Q3 |
| We finished the year with a very favorable quarter, driven by continued strength in our sleep and respiratory product lines and the expected improvement in our Humana contract |
| We do think that the second half of the year will do a bit better than the first half |
| We outperformed our expectations due to increased revenue, especially in high margin categories, improvement in our Humana contract to original expectations, improvement in COGS, and improvements in labor and operating expenses |
| We believe we can overcome any reduction in the growth of CPAP usage by continuing to increase our share of the market through enhanced traditional sales efforts and enterprise sales, decreased operating costs through automation and better processes, and increased focus on patient adherence and retention |
| And we think that's a good thing obviously for our patients and then certainly for our economics |
| So that's a pillar of why we think we can ultimately get back to more growth so that we see as upside for going forward |
| AdaptHealth's net revenue grew 7.7% over 2022 and non-acquired growth was 7.3% led by our sleep and respiratory product categories |
| We’ve improved on each of these measures over the past few years, and the GLP-1 conversation has expedited our progress in these basic areas |
| Statement |
|---|
| Our diabetes revenue was down 3.8% against the fourth quarter of 2022 |
| If you're getting down to the quarter level, certainly q1 is pressured, as we called out |
| As expected, we continued to absorb pressure in our pump and pump supply revenue as the market shifted toward tubeless pumps |
| The 75/25 reimbursement for non-competitively bid, non-rural MSA expired on January 1st, and although it is possible the rates will still be extended we are budgeting approximately $25 million of headwind to revenue and to adjusted EBITDA |
| And then secondly, in CGMs, we think growth will be lighter in the first half as sales team starts ramping, and then we'll deliver in Q4, so Q3 and Q4 |
| We know that one of the risks in healthcare is reimbursement changes and the non-expansion of the 75/25 rate relief masks growth rates that would have been more expected in 2024 considering the tough comparables in sleep and respiratory |
| And so as we far outpace the patient transitions that we committed to as part of a key agreement in Q4, those cap deductions came down significantly |
| Within rental revenue the nuance of the 13-month rental cycle means that the record setups we reported in the first half of 2023 are rolling off of that rental revenue in 2024 and so it's creating just a tough comp |
| First, there seems to be a consensus that GLP-1s will not have a negative effect on CGM growth |
| Going back to sleep rentals for a second, I understand the flat growth guidance for 2024 just due to really tough comps in 2023 |
| We also recorded a $25 million pretax charge to settle a pending securities action filed in 2021 premised on allegations regarding disclosures related to our former CEO and organic growth |
| You got the pump pressures we think will be heavier in the first half and lighter in the second half |
| And that’s really the people and the processes within the rev cycle have brought down DSOs |
| As a result, our net leverage decreased from 3.69x to 3.16x and we expect to be below 3x before the end of this year |
| But again, this is not anything other than a tough comp period and just larger number of patients rolling off from a year ago |
| I apologize |
| We had briefly talked about a $35 million to $40 million headwind and it literally came square in the middle of that |
| First one on pumps, in the past you did give some revenue numbers and headwind expectations for 2023 |
| Actual results could differ materially from those projected in the forward-looking statements because of a number of risk factors and uncertainties, which are discussed at length in the company’s annual and quarterly SEC filings |
| We think, as we stand here today that the headwind in 2024 will be about half that, so called in the range of high teens to $20 million |
Please consider a small donation if you think this website provides you with relevant information